Crinetics Pharmaceuticals (CRNX) Return on Capital Employed (2018 - 2026)
Crinetics Pharmaceuticals (CRNX) recorded quarterly Return on Capital Employed of 45.76% in Q1 2026, up 4.72% quarter-over-quarter from 48.02% in Q4 2025, and down 1766.0% on a YoY basis from 2.75% in Q1 2025.
Crinetics Pharmaceuticals (CRNX) Return on Capital Employed (2018 - 2026) Analysis & Trends
Crinetics Pharmaceuticals' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 45.76% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 1766.0% year-over-year to 45.76%; the TTM figure through Mar 2026 stood at 45.76% (down 1766.0% YoY), while the FY2025 annual figure was 43.23%, down 849.0% from the prior year.
- Return on Capital Employed was 45.76% for Q1 2026 at Crinetics Pharmaceuticals, up from 48.02% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 28.1% in Q1 2025 to a low of 70.84% in Q2 2023.
- Historically, Return on Capital Employed has averaged 41.52% across 5 years, with a median of 38.58% in 2022.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed sank 3226 bps in 2023, then jumped 4004 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 49.26% in 2022, then rose by 24 bps to 37.44% in 2023, then advanced by 20 bps to 30.09% in 2024, then sank by 60 bps to 48.02% in 2025, then rose by 5 bps to 45.76% in 2026.
- The last three Return on Capital Employed figures came in at 45.76% (Q1 2026), 48.02% (Q4 2025), and 40.89% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Crinetics Pharmaceuticals | 3.75 Bn | 3.75 Bn | 10.53 Mn | -45.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.76% |
| Dec 31, 2025 | -48.02% |
| Sep 30, 2025 | -40.89% |
| Jun 30, 2025 | -33.65% |
| Mar 31, 2025 | -28.10% |
| Dec 31, 2024 | -30.09% |
| Sep 30, 2024 | -34.75% |
| Jun 30, 2024 | -30.80% |
| Mar 31, 2024 | -32.87% |
| Dec 31, 2023 | -37.44% |
| Sep 30, 2023 | -48.60% |
| Jun 30, 2023 | -70.84% |
| Mar 31, 2023 | -59.34% |
| Dec 31, 2022 | -49.26% |
| Sep 30, 2022 | -39.92% |
| Jun 30, 2022 | -38.58% |
| Mar 31, 2022 | -36.85% |
| Dec 31, 2021 | -40.77% |
| Sep 30, 2021 | -49.13% |
| Jun 30, 2021 | -50.05% |